New breast cancer cocktail aims to ditch chemo before surgery
NCT ID NCT07290166
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This phase II trial tests a combination of targeted drugs and hormone therapy given before surgery for a specific type of breast cancer (ER-positive, HER2-positive). The goal is to shrink tumors without using standard chemotherapy. The study will enroll 42 women and measure how many achieve a complete response in the breast tissue. If it works, this approach could spare patients from chemo side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab, pertuzumab, pyrotinib, CDK4/6 inhibitor, and endocrine therapy
What this could lead to
If successful, this could offer a chemotherapy-free option for certain breast cancer patients, potentially reducing side effects while still shrinking tumors before surgery.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The combination also carries risks like heart problems, diarrhea, and low blood cell counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.